C07K 14/4727
Mucins
Official title: {Mucins, e.g. human intestinal mucin}
C07K14/4727 (Mucins) appears on 179 US grants and 282 published applications in this corpus.
Search patents in C07K- Granted patents
- 179
- Published applications
- 282
- Assignees
- 138
- Inventors
- 377
- Latest grant
- 11 Aug 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1984 | 1 | 0 |
| 1985 | 0 | 0 |
| 1986 | 0 | 0 |
| 1987 | 0 | 0 |
| 1988 | 0 | 0 |
| 1989 | 0 | 0 |
| 1990 | 0 | 0 |
| 1991 | 0 | 0 |
| 1992 | 0 | 0 |
| 1993 | 0 | 0 |
| 1994 | 2 | 0 |
| 1995 | 0 | 0 |
| 1996 | 0 | 0 |
| 1997 | 4 | 0 |
| 1998 | 5 | 0 |
| 1999 | 3 | 0 |
| 2000 | 6 | 0 |
| 2001 | 4 | 0 |
| 2002 | 2 | 7 |
| 2003 | 3 | 13 |
| 2004 | 4 | 11 |
| 2005 | 2 | 13 |
| 2006 | 5 | 13 |
| 2007 | 3 | 6 |
| 2008 | 2 | 4 |
| 2009 | 4 | 14 |
| 2010 | 9 | 11 |
| 2011 | 7 | 12 |
| 2012 | 5 | 14 |
| 2013 | 9 | 15 |
| 2014 | 5 | 12 |
| 2015 | 12 | 14 |
| 2016 | 11 | 17 |
| 2017 | 9 | 14 |
| 2018 | 8 | 5 |
| 2019 | 7 | 9 |
| 2020 | 9 | 15 |
| 2021 | 13 | 14 |
| 2022 | 6 | 16 |
| 2023 | 5 | 15 |
| 2024 | 5 | 5 |
| 2025 | 5 | 8 |
| 2026 | 4 | 5 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Recombinant mucins, and compositions and methods for using the same11 Aug 2026US 12,703,727 B2Cornell University
- Chimeric Tim receptors and uses thereof9 Jun 2026US 12,648,964 B2Cero Therapeutics Holdings, Inc.
- Humanized antibodies to mucin-16 and methods of use thereof5 May 2026US 12,617,866 B2Eureka Therapeutics, Inc.
- Compositions derived from gastrointestinal tract mucins17 Feb 2026US 12,550,924 B2Gnubiotics Sciences SA
- Anti-MUC16 antibodies and uses thereof11 Nov 2025US 12,466,894 B2Memorial Sloan Kettering Cancer Center
- Compositions derived from gastrointestinal tract mucins3 Sep 2026US 2026/0256177 A1Gnubiotics Sciences SA
- Chimeric tim receptors and uses thereof11 Jun 2026US 2026/0158069 A1Cero Therapeutics Holdings, Inc.
- Colon and Pancreas Cancer Peptidomimetics23 Apr 2026US 2026/0109745 A1Precision Biologics, Inc.
- Personalized muc1-c induced pluripotent stem cell and dendritic cell based vaccines16 Apr 2026US 2026/0103495 A1Dana-Farber Cancer Institute, Inc.
- Vaccine against pancreatic cancer, and medical use thereof12 Feb 2026US 2026/0041749 A1Yuanben (Zhuhai Hengqin) Biotechnology Co., Ltd.
Most cited
By later US patents
- Pharmaceutical composition containing a stabilised mRNA optimised for translation in its coding regions75US 10,188,748 B2CureVac AG · 2019
- DNA sequence encoding a selectin ligand73US 5,304,640 AGenentech, Inc. · 1994
- Chemokine-tumor antigen fusion proteins as cancer vaccines55US 6,562,347 B1The United States of America as represented by the Department of Health and Human Services · 2003
- Sterilized preserved, stable mucine-containing solutions50US 4,438,100 AA/S Orthana Kemisk Fabrik · 1984
- Human cytotoxic T-lymphoctye epitope and its agonist eptiope from the non-variable number of tandem repeat sequence of MUC-139US 7,999,071 B2The United States of America, as represented by the Secretary, Department of Health and Human Services · 2011